No Data
No Data
Outlook Therapeutics Reports Strong Earnings and Strategic Progress
Outlook Therapeutics | 10-Q: Quarterly report
Outlook Therapeutics Reports Q1 Adjusted EPS (89c) Vs. (78c) Last Year
Outlook Therapeutics Announces Upcoming Anticipated Milestones
Outlook Therapeutics Advances ONS-5010 / LYTENAVA BLA Resubmission and Prepares for European Commercial Launch in 2025
Express News | Outlook Therapeutics Inc -Qtrly Shr $0.72